cycrimine
Trade name: pagitane
Small moleculeapproved
Approved
Jul 22, 1953
CYCRIMINE is an antispasmodic drug used for the treatment of Parkinson's disease (PD). It binds the muscarinic acetylcholine receptor M1, effectively reducing levels of acetylcholine. This decrease in acetylcholine restores the normal dopamine-acetylcholine balance and relieves the symptoms of PD. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
Indications
Approved for
Mechanism of action
- Muscarinic acetylcholine receptor M1ANTAGONIST
CHRM1 antagonist
Indicated for Parkinson's disease, M1 likely responsible
Approval history
- approvedJul 22, 1953
Chemistry & pharmacology
Loading structure…
SMILES
OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1- Mol. weight
- 287.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1201227 ↗
- WikipediaCycrimine ↗
- NCATS543567RFQQ ↗
- ChEMBLCHEMBL1200828 ↗
Also known as
- alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol
- alpha-cyclopentyl-alpha-phenyl-1-piperidinepropanol
- cicrimina
- cicrimina
- cycrimine
- cycrimine
- cycrimine
- cycrimine
- cycrimine
- cycrimine
- cycrimine
- cycrimine
- (+-)-cycrimine
- (+-)-cycrimine
- cycrimine hcl
- cycrimine hcl
- cycrimine hcl
- cycrimine hydrochloride
- cycrimine hydrochloride
- cycrimine hydrochloride
- cycrimine hydrochloride
- cycriminum
- cycriminum
- pagitane
- pagitane
- pagitane
- pagitane
Organizations
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Eli Lilly | For profit | NDA | Jul 22, 1953 |